CSC
BCLI

Caldwell Sutter Capital’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Caldwell Sutter Capital’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-157,009
Closed – – 871
2025
Q2 		$0 Hold
157,009
– – ﹤0.01% 863
2025
Q1 		$0 Hold
157,009
– – ﹤0.01% 889
2024
Q4 		$0 Buy
+157,009
New +$290K ﹤0.01% 899
2024
Q3 		– Sell
-10,467
Closed – – 908
2024
Q2 		$0 Hold
10,467
– – ﹤0.01% 925
2024
Q1 		$0 Hold
10,467
– – ﹤0.01% 924
2023
Q4 		$0 Hold
10,467
– – ﹤0.01% 954
2023
Q3 		$0 Hold
10,467
– – ﹤0.01% 888
2023
Q2 		$0 Hold
10,467
– – ﹤0.01% 865
2023
Q1 		$0 Buy
+10,467
New +$304K ﹤0.01% 565

Other funds holding BCLI

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Caldwell Sutter Capital's BCLI Position: Q3 2025 in Review

Caldwell Sutter Capital sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 157,009 shares.

Caldwell Sutter Capital first reported a position in BCLI in Q1 2023 and held it in 9 quarters. The position peaked at $0 in Q2 2025. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

  • Caldwell Sutter Capital reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
  • Caldwell Sutter Capital sold 157,009 BRAINSTORM CELL THERAPUTC shares in Q3 2025.
  • Caldwell Sutter Capital first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2023 and held it in 9 quarters.
  • Caldwell Sutter Capital's BRAINSTORM CELL THERAPUTC position peaked at $0 in Q2 2025.
  • 5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Caldwell Sutter Capital's 13F filing for Q3 2025, filed 29 Oct 2025.